RxDoctor Payments Data

Rebecca Ahdoot, MD

Nephrology · Orange, CANPI 1851735211

Payments from drug & device makers

$127,749in general payments, 2019–2025

Across 168 payments — averaging $760.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$62K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$42K
  • Otsuka America Pharmaceutical, Inc.$9K
  • Boehringer Ingelheim$6K
  • Lilly USA, LLC$5K
  • Aurinia Pharma U.S., Inc.$1K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$23,49636%
  • Speaking & faculty fees$31,72048%
  • Travel & lodging$4,6927%
  • Food & beverage$6,0699%
  • Education$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,749 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$164,178
Medicare patients
347
Services billed
1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide73$220,650
LokelmaSodium Zirconium Cyclosilicate105$79,053
FarxigaDapagliflozin Propanediol14$11,681
Sevelamer Carbonate25$5,774
Torsemide155$2,824
Midodrine Hcl29$2,010
Losartan Potassium89$1,470
Calcium Acetate26$1,335
Nifedipine ErNifedipine36$1,296
Metoprolol Succinate54$683
Hydralazine Hcl49$548
Metolazone12$537
Amlodipine Besylate128$521
Tamsulosin Hcl55$457
Calcitriol24$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$272$220,65073 claims
AstraZenecaLokelma, Farxiga$751$90,735119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →